Key result
One-year major event risk in DCM falls ~3% annually over a 12-year period.
Why the study?
Temporal trends in clinical composition and outcome in dilated cardiomyopathy remain largely unknown despite advances in heart failure management.
Observational (n=7,873)
Yes
Effect estimate: RR 0.97 (95% CI 0.96-0.98)
Absolute Event Rate: 63.1% vs 80.6%
p-value: p=<0.0001
From 2003 to 2015, patients with dilated cardiomyopathy in Sweden exhibited a less severe clinical phenotype and experienced declining mortality and hospitalizations, reflecting improvements in heart failure management.
Declining dilated cardiomyopathy risks may reflect care advances; leaves open causal drivers in this observational cohort.
BACKGROUND: Temporal trends in clinical composition and outcome in dilated cardiomyopathy (DCM) are largely unknown, despite considerable advances in heart failure management. We set out to study clinical characteristics and prognosis over time in DCM in Sweden during 2003-2015. METHODS: DCM patients (n = 7873) from the Swedish Heart Failure Registry were divided into three calendar periods of inclusion, 2003-2007 (Period 1, n = 2029), 2008-2011 (Period 2, n = 3363), 2012-2015 (Period 3, n = 2481). The primary outcome was the composite of all-cause death, transplantation and hospitalization during 1 year after inclusion into the registry. RESULTS: Over the three calendar periods patients were older (p = 0.022), the proportion of females increased (mean 22.5%, 26.4%, 27.6%, p = 0.0001), left ventricular ejection fraction was higher (p = 0.0014), and symptoms by New York Heart Association less severe (p < 0.0001). Device (implantable cardioverter defibrillator and/or cardiac resynchronization) therapy increased by 30% over time (mean 11.6%, 12.3%, 15.1%, p < 0.0001). The event rates for mortality, and hospitalization were consistently decreasing over calendar periods (p < 0.0001 for all), whereas transplantation rate was stable. More advanced physical symptoms correlated with an increased risk of a composite outcome over time (p = 0.0043). CONCLUSIONS: From 2003 until 2015, we observed declining mortality and hospitalizations in DCM, paralleled by a continuous change in both demographic profile and therapy in the DCM population in Sweden, towards a less affected phenotype.
No takes yet. Share an insight, caveat, or question.
Sjöland et al. (2021) conducted an observational in Dilated cardiomyopathy (DCM) (n=7,873). Later calendar period (2012-2015) vs. Earlier calendar period (2003-2007) was evaluated on Composite of all-cause death, transplantation and hospitalization during 1 year (RR 0.97, 95% CI 0.96-0.98, p=<0.0001). Over a 12-year period, the 1-year risk of the composite of all-cause death, transplantation, and hospitalization in patients with dilated cardiomyopathy decreased significantly (RR 0.97 per year).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: